Regulatory

Regulatory

Navamedic ASA: Updated key information relating to the rights issue

Navamedic ASA – Additional underwriting commitments in the Rights Issue

Navamedic ASA: First approval of the medical device OraFID® as primary package for a pharmaceutical product

Navamedic ASA – Investor presentation regarding the acquisition of the business of dne pharma AS

Navamedic ASA: Mandatory notice of trade

Navamedic ASA: Notice of extraordinary general meeting on 14 July 2025 in connection with a contemplated rights issue